$0.08 Earnings Per Share Expected for Genmab A/S (NASDAQ:GMAB) This Quarter

Wall Street analysts forecast that Genmab A/S (NASDAQ:GMAB) will announce $0.08 earnings per share for the current quarter, Zacks reports. Four analysts have issued estimates for Genmab A/S’s earnings. The highest EPS estimate is $0.10 and the lowest is $0.06. Genmab A/S reported earnings of $0.76 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 89.5%. The firm is expected to announce its next quarterly earnings report on Wednesday, August 11th.

On average, analysts expect that Genmab A/S will report full year earnings of $0.57 per share for the current fiscal year, with EPS estimates ranging from $0.37 to $0.79. For the next fiscal year, analysts anticipate that the company will report earnings of $0.73 per share, with EPS estimates ranging from $0.59 to $0.98. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Genmab A/S.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.22. Genmab A/S had a net margin of 51.35% and a return on equity of 29.11%. The firm had revenue of $256.24 million during the quarter, compared to analysts’ expectations of $214.90 million.

GMAB has been the subject of a number of research analyst reports. SVB Leerink reduced their price objective on shares of Genmab A/S from $38.00 to $36.00 and set a “market perform” rating for the company in a research report on Thursday, February 25th. Danske upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, February 24th. TheStreet upgraded shares of Genmab A/S from a “c” rating to a “b” rating in a research report on Monday, May 24th. Truist upped their price objective on shares of Genmab A/S from $42.00 to $47.00 in a research report on Thursday, February 25th. Finally, UBS Group restated a “buy” rating on shares of Genmab A/S in a research report on Monday. Two analysts have rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $42.13.

Shares of GMAB traded up $0.16 during trading hours on Friday, hitting $43.79. The stock had a trading volume of 18,852 shares, compared to its average volume of 543,409. The business’s 50-day moving average is $37.45. Genmab A/S has a fifty-two week low of $29.06 and a fifty-two week high of $44.83. The firm has a market cap of $28.74 billion, a price-to-earnings ratio of 33.56, a price-to-earnings-growth ratio of 2.69 and a beta of 0.89.

Several institutional investors and hedge funds have recently made changes to their positions in GMAB. San Francisco Sentry Investment Group CA purchased a new stake in shares of Genmab A/S in the fourth quarter valued at about $32,000. JPMorgan Chase & Co. grew its holdings in shares of Genmab A/S by 49.0% in the fourth quarter. JPMorgan Chase & Co. now owns 827 shares of the company’s stock valued at $33,000 after purchasing an additional 272 shares during the period. Captrust Financial Advisors grew its holdings in shares of Genmab A/S by 164.5% in the first quarter. Captrust Financial Advisors now owns 1,058 shares of the company’s stock valued at $35,000 after purchasing an additional 658 shares during the period. Veriti Management LLC purchased a new position in Genmab A/S during the fourth quarter worth about $42,000. Finally, Penserra Capital Management LLC boosted its stake in Genmab A/S by 192.1% during the fourth quarter. Penserra Capital Management LLC now owns 1,075 shares of the company’s stock worth $43,000 after buying an additional 707 shares during the period. 6.42% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL.

Recommended Story: What is the Bid-Ask Spread?

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.